Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study

1. Bazinet, A.
2. Darbaniyan, F.
3. Jabbour, E.
4. Montalban-Bravo, G.
5. Ohanian, M.
6. Chien, K.
7. Kadia, T.
8. Takahashi, K.
9. Masarova, L.
10. Short, N.
11. Alvarado, Y.
12. Yilmaz, M.
13. Ravandi, F.
14. Andreeff, M.
15. Kanagal-Shamanna, R.
16. Ganan-Gomez, I.
17. Colla, S.
18. Qiao, W.
19. Huang, X.
20. McCue, D.
21. Mirabella, B.
22. Kantarjian, H.
23. Garcia-Manero, G.